Platinum analogues in preclinical and clinical development.
The impact of cisplatin on chemotherapy for solid tumors has led to the synthesis of many molecules with platinum as their central building block. These so-called platinum analogues have been developed with the obvious goals of improving the antitumor activity of cisplatin and hopefully, at the same time, altering the dose-limiting side effects of the prototype drug. At least 10 such molecules are in clinical development, whereas several others are at various stages of preclinical testing.
Hamilton
T C
TC
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111.
O'Dwyer
P J
PJ
Ozols
R F
RF
D000818:Animals; D002945:Cisplatin / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D002986:Clinical Trials as Topic; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009944:Organoplatinum Compounds / Q000627:therapeutic use* / Q000633:toxicity
D009944:Organoplatinum Compounds; D002945:Cisplatin